Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 10/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.61 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862285 | 1.00 | TLR7 (0.61) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3862599 | 0.87 | TLR7 (0.69) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3862600 | 0.87 | TLR7 (0.69) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3863511 | 0.85 | TLR7 (0.72) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3864348 | 0.83 | TLR7 (0.69) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3864164 | 0.81 | TLR7 (0.60) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3864162 | 0.81 | TLR7 (0.60) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL4539881 | 0.81 | TLR7 (0.65) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL4524701 | 0.81 | TLR7 (0.65) | TLR7ADORA2APDE4DLMNAPOLB | |
| SCHEMBL3861219 | 0.80 | TLR7 (0.71) | TLR7ADORA2APDE4DLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | TLR7 68/4885ADORA2A 2283/4885PDE4D 2699/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | TLR7 68/4885ADORA2A 2283/4885PDE4D 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.